RenaissThera - Innovation for underserved

About Us

Pharmaceutical company developing affordable innovative Therapies

Pharmaceutical companies have predominantly concentrated on developing innovative therapies in developed countries, where the cost of development is relatively high, resulting in higher price points that are often unaffordable in many regions globally. This creates a significant delay in access to these novel branded therapies for patients, particularly where insurance coverage is limited. Despite the increasing emphasis on biotech products across various therapy areas, many patients still lack access to these targeted therapies even after generic versions become available, as biosimilars also remain expensive in out-of-pocket settings.

There is a significant need to develop affordable solutions to ensure broader access to innovative pharmacotherapies. Our approach involves developing cost-effective, innovative therapies that serve as alternatives to expensive treatments by prioritizing low-risk, proven pathways and focusing on cost-effective development strategies.

To serve the needy patients globally

Lower-income countries have significantly lower access to innovative therapies, and the specific needs of these markets are not prioritized while developing these therapies. Certain emerging markets present significant opportunities for innovation due to their high demand for prevalent diseases, increasing purchasing power, and well-established healthcare infrastructure for clinical development. We primarily develop therapies in these emerging markets where development costs are comparatively lower so that we can serve broader low-income population with these affordable solutions. We plan to launch these proven therapies globally as affordable alternatives in relevant disease areas.

In the cardio-metabolic therapy area

Obesity, diabetes and related comorbidities are the largest therapy areas with high unmet needs across the globe, with continued innovations across therapies. There is a growing trend of innovation in specialty therapies, particularly with biotech solutions catering to high-income population with new brands, while low-income markets are left behind with significant unmet needs. Our focus lies in areas where complex molecules and expensive therapies have already been largely implemented, leaving limited options for patients with low income. We identify prevalent disease areas lacking access to therapies for the broader population, enabling us to provide them with affordable innovations.

By innovation in small molecule targeted therapies

Small molecule provide affordable alternatives for proven pathways, as development is relatively faster and manufacturing is less complicated. Most of these products can be administered orally requiring lesser monitoring without hospital settings for adverse events. We focus on all possible options for innovation in small molecule NME-targeted therapies as a safer and effective alternatives. We adopt a relatively low-risk strategy by focusing on validated pathways providing alternatives that are currently inaccessible to a wider population.

Leveraging AI platform to accelerate the target and drug discovery

Generative AI is transforming pharmaceutical research and development by speeding up the process of target discovery and development timelines. This advancement facilitates the quicker introduction of affordable innovations to the market, potentially expanding access to therapies. Our technology partner has established AI platform well tested for approved therapies helping us in faster identification of validated targets with low-risk and novel molecules with structure activity relationship. It also helps us design and optimize molecules very efficiently reducing overall turn-around time for drug discovery.